Nia Layan Hamidi, Alqudah Sara, Markley Rachel L, DeLucia Beckey, Bobba Viharika, Elmallah Judi, Nemet Ina, Sangwan Naseer, Claesen Jan
Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic, Cleveland, OH 44195, USA.
Department of Chemical and Biomedical Engineering, Cleveland State University, Cleveland, OH 44115, USA.
bioRxiv. 2025 May 19:2025.05.18.654755. doi: 10.1101/2025.05.18.654755.
Nisin Z, an antimicrobial metabolite produced by has been safely used as a food preservative for many years. Nisin Z also showed promising activity against various cancer types , and significantly reduced tumor size in an ectopic head and neck cancer model. Here, we investigate the activity of nisin Z for colorectal cancer treatment and observed an reduction in cellular proliferation, and a moderate enhancement in cell death. We next analyzed the effect of oral nisin Z administration in the Apc intestinal adenoma mouse model. We measured tumor burden along the gastrointestinal tract and observed a decrease in tumor burden in the middle region of the small intestine, but not in the lower region or colon. Since tumor progression in the Apc model is exacerbated by an inflammatory environment, we next determined whether nisin Z impacts this in a direct or indirect manner. We show that nisin Z can directly reduce NF-κB activation in a dose-dependent manner. In addition, nisin Z impacted the cecal microbiome composition as well as microbiota-associated plasma metabolites, causing an overall shift towards a more health-associated profile. Interestingly, the Apc genotype differentially impacted the nisin Z-mediated differences in cecal microbiome composition and plasma metabolites compared to wildtype animals. In summary, our data suggest that the reduction in small intestinal tumor burden could be due to nisin Z's contribution to a reduced pro-inflammatory environment. Future studies will reveal whether nisin's localized effect is due to degradation of the peptidic compound in more distal regions of the gastrointestinal tract and focus on development of delivery systems to increase efficacy.
With the increased incidence of colorectal cancer, especially among younger individuals, it is critical to study approaches that help with the prevention and treatment of this debilitating disease. Our study indicates that nisin Z, a bacterially produced peptide antibiotic, decreases the growth of colorectal cancer cells and moderately increases cell death . Oral administration of nisin Z in an intestinal adenoma mouse model revealed a reduction of tumor burden in the middle region of the small intestine. This decreased tumor burden might in part be attributed to a direct anti-inflammatory effect, as well as an indirect effect on the gut microbiota and their metabolites due to nisin Z's antibacterial activity. Overall, we demonstrate a potential activity for nisin Z in the prevention or amelioration of inflammation-associated colorectal cancer, underscoring the significance of investigating the properties of bacterial natural products in human health.
乳链菌肽Z是由[具体细菌名称未给出]产生的一种抗菌代谢产物,多年来一直被安全地用作食品防腐剂。乳链菌肽Z对多种癌症类型也显示出有前景的活性,并且在异位头颈癌模型中显著减小了肿瘤大小。在此,我们研究了乳链菌肽Z对结直肠癌治疗的活性,并观察到细胞增殖减少以及细胞死亡有适度增强。接下来,我们分析了口服乳链菌肽Z在Apc肠道腺瘤小鼠模型中的作用。我们测量了沿胃肠道的肿瘤负荷,观察到小肠中部区域的肿瘤负荷降低,但在下部区域或结肠中未降低。由于Apc模型中的肿瘤进展会因炎症环境而加剧,我们接下来确定乳链菌肽Z是以直接还是间接方式影响这一过程。我们表明乳链菌肽Z能以剂量依赖方式直接降低NF-κB的激活。此外,乳链菌肽Z影响了盲肠微生物群组成以及与微生物群相关的血浆代谢物,导致整体向更健康相关的谱型转变。有趣的是,与野生型动物相比,Apc基因型对乳链菌肽Z介导的盲肠微生物群组成和血浆代谢物差异有不同影响。总之,我们的数据表明小肠肿瘤负荷的降低可能归因于乳链菌肽Z对促炎环境减少的贡献。未来的研究将揭示乳链菌肽的局部作用是否是由于胃肠道更远端区域肽类化合物的降解,并将专注于开发递送系统以提高疗效。
随着结直肠癌发病率的增加,尤其是在年轻个体中,研究有助于预防和治疗这种使人衰弱疾病的方法至关重要。我们的研究表明,细菌产生的肽抗生素乳链菌肽Z可降低结直肠癌细胞生长并适度增加细胞死亡。在肠道腺瘤小鼠模型中口服乳链菌肽Z显示小肠中部区域的肿瘤负荷降低。这种肿瘤负荷的降低可能部分归因于直接的抗炎作用,以及由于乳链菌肽Z的抗菌活性对肠道微生物群及其代谢物的间接作用。总体而言,我们证明了乳链菌肽Z在预防或改善炎症相关结直肠癌方面的潜在活性,强调了研究细菌天然产物在人类健康中的特性的重要性。